Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer
Patent No. EP3725810 (titled "Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer") was filed by Astellas Pharma on May 21, 2013. The application was issued on Jul 6, 2022.
Patent Summary
Enhancing the effectiveness of cancer immunotherapy by combining an anti-CLDN18.2 antibody with agents that stimulate gamma delta T cells and optionally chemotherapeutic agents that stabilize CLDN18.2 expression. This synergistic treatment approach leverages the antibody's ability to bind CLDN18.2, a gastric cancer antigen, with agents that activate gamma delta T cells and potentially increase CLDN18.2 expression on cancer cells. The combination improves cancer cell killing by the antibody and immune response.
Patent Family
Patent Oppositions (2)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3725810
- Application Number
- EP20163993A
- Filing Date
- May 21, 2013
- Status
- Revoked
- Jan 3, 2025
- Publication Date
- Jul 6, 2022
- External Links
- Slate, Register , Google Patents